LT2882440T - Farmaciniai deriniai, apimantys b-raf slopiklį, egfr slopiklį ir nebūtinai pi3k-alfa slopiklį - Google Patents

Farmaciniai deriniai, apimantys b-raf slopiklį, egfr slopiklį ir nebūtinai pi3k-alfa slopiklį

Info

Publication number
LT2882440T
LT2882440T LTEP13748243.6T LT13748243T LT2882440T LT 2882440 T LT2882440 T LT 2882440T LT 13748243 T LT13748243 T LT 13748243T LT 2882440 T LT2882440 T LT 2882440T
Authority
LT
Lithuania
Prior art keywords
inhibitor
pi3k
optionally
alpha
pharmaceutical combinations
Prior art date
Application number
LTEP13748243.6T
Other languages
English (en)
Lithuanian (lt)
Inventor
Giordano Caponigro
Darrin Stuart
Laure Moutouh-De Parseval
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48980368&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2882440(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of LT2882440T publication Critical patent/LT2882440T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
LTEP13748243.6T 2012-08-07 2013-08-05 Farmaciniai deriniai, apimantys b-raf slopiklį, egfr slopiklį ir nebūtinai pi3k-alfa slopiklį LT2882440T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261680473P 2012-08-07 2012-08-07
PCT/US2013/053619 WO2014025688A1 (en) 2012-08-07 2013-08-05 Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor

Publications (1)

Publication Number Publication Date
LT2882440T true LT2882440T (lt) 2019-04-25

Family

ID=48980368

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP13748243.6T LT2882440T (lt) 2012-08-07 2013-08-05 Farmaciniai deriniai, apimantys b-raf slopiklį, egfr slopiklį ir nebūtinai pi3k-alfa slopiklį

Country Status (39)

Country Link
US (1) US9474754B2 (OSRAM)
EP (2) EP3574904A1 (OSRAM)
JP (3) JP6342396B2 (OSRAM)
KR (1) KR102112885B1 (OSRAM)
CN (1) CN104519887B (OSRAM)
AR (1) AR092045A1 (OSRAM)
AU (1) AU2013299841B8 (OSRAM)
CA (1) CA2879548C (OSRAM)
CL (1) CL2015000294A1 (OSRAM)
CO (1) CO7200273A2 (OSRAM)
CY (1) CY1122143T1 (OSRAM)
DK (1) DK2882440T3 (OSRAM)
EA (1) EA028420B1 (OSRAM)
EC (1) ECSP15008695A (OSRAM)
ES (1) ES2717911T3 (OSRAM)
GT (1) GT201500025A (OSRAM)
HK (1) HK1211831A1 (OSRAM)
HR (1) HRP20190537T1 (OSRAM)
HU (1) HUE042877T2 (OSRAM)
IL (1) IL236934B (OSRAM)
IN (1) IN2015DN00450A (OSRAM)
JO (1) JOP20130236B1 (OSRAM)
LT (1) LT2882440T (OSRAM)
MA (1) MA37829A1 (OSRAM)
MX (1) MX359403B (OSRAM)
MY (1) MY176031A (OSRAM)
NZ (1) NZ703940A (OSRAM)
PE (2) PE20150673A1 (OSRAM)
PH (1) PH12015500246A1 (OSRAM)
PL (1) PL2882440T3 (OSRAM)
PT (1) PT2882440T (OSRAM)
RS (1) RS58734B1 (OSRAM)
SG (1) SG11201500321YA (OSRAM)
SI (1) SI2882440T1 (OSRAM)
TN (1) TN2015000027A1 (OSRAM)
TR (1) TR201904980T4 (OSRAM)
TW (1) TWI607754B (OSRAM)
UA (1) UA115786C2 (OSRAM)
WO (1) WO2014025688A1 (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA028420B1 (ru) * 2012-08-07 2017-11-30 Новартис Аг Фармацевтические комбинации, содержащие ингибитор b-raf, ингибитор egfr и, необязательно, ингибитор pi3k-альфа
PL2976106T3 (pl) 2013-03-21 2021-10-25 Array Biopharma Inc. Terapia kombinowana obejmująca inhibitor B-Raf i drugi inhibitor
WO2015145388A2 (en) * 2014-03-27 2015-10-01 Novartis Ag Methods of treating colorectal cancers harboring upstream wnt pathway mutations
DK3155126T3 (en) * 2014-06-16 2018-09-03 Worldwide Innovative Network METHOD OF CHOOSING PERSONAL TRIAL TREATMENT FOR CANCER TREATMENT
WO2016193955A1 (en) * 2015-06-04 2016-12-08 Giorgio Stassi Combinations of kinase inhibitors for treating colorectal cancer
EP3355886A1 (en) * 2015-08-28 2018-08-08 Novartis AG Pharmaceutical combination comprising the pi3k inhibitor alpelisib and the b-raf inhibitor dabrafenib; the use of such combination in the treatment or prevention of cancer
JP2018526375A (ja) * 2015-08-28 2018-09-13 ノバルティス アーゲー 組み合わせ療法
WO2017066664A1 (en) * 2015-10-16 2017-04-20 Millennium Pharmaceuticals, Inc. Combination therapy including a raf inhibitor for the treatment of colorectal cancer
MX387795B (es) 2016-06-03 2025-03-19 Array Biopharma Inc Combinaciones farmaceuticas.
AU2017329090B9 (en) * 2016-09-19 2019-09-05 Novartis Ag Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
MX393855B (es) 2017-05-02 2025-03-21 Novartis Ag Terapia de combinación que comprende un inhibidor de raf y trametinib
EP3661516A1 (en) * 2017-08-03 2020-06-10 Novartis AG Therapeutic combination of a third-generation egfr tyrosine kinase inhibitor and a raf inhibitor
SI3860998T1 (sl) 2018-10-05 2024-06-28 Annapurna Bio Inc. Spojine in sestavki za zdravljenje stanj, povezanih z aktivnostjo apj-receptorja
TWI849043B (zh) * 2019-01-25 2024-07-21 英屬開曼群島商百濟神州有限公司 B-raf激酶二聚體抑制劑之穩定固體分散體、製備方法及其用途
WO2020164997A1 (en) * 2019-02-12 2020-08-20 Bayer Aktiengesellschaft Combination of pi3k-inhibitors
AU2020276695B2 (en) 2019-05-13 2025-12-18 Novartis Ag New crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as RAF inhibitors for the treatment of cancer
JPWO2023145530A1 (OSRAM) * 2022-01-27 2023-08-03
WO2023230554A1 (en) 2022-05-25 2023-11-30 Pfizer Inc. Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
WO2024073364A1 (en) * 2022-09-26 2024-04-04 Beigene, Ltd. Combinations of a b-raf inhibitor, and an anti-egfr antibody for the treatment of cancer
WO2025003956A1 (en) 2023-06-30 2025-01-02 Pfizer Inc. High drug loading formulations of encorafenib
WO2025262686A1 (en) * 2024-06-20 2025-12-26 Ilan Paz Devices, systems and methods for optimized, personalized administration of oral dosage forms

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
RS52939B (sr) 2007-04-10 2014-02-28 Exelixis Inc. Postupci za lečenje kancera upotrebom piridopirimidinonskih inhibitora pi3k alfa
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
BR112012003926A2 (pt) * 2009-08-24 2020-08-11 Genentech Inc método para identificar um paciente não responsivo ao tratamento com um inibidor de b-raf, método para determinar se um tumor irá responder ao tratamento com um inibidor de b-raf, método para predizer se um paciente será não responsivo ao tratamento com um inibidor de braf específico, kit, método para classificar um tumor de mama, pulmão, cólon, ovário, tiroide, melanoma, ou pancreático e método para identificar um tumor não responsivo ao tratamento com um inibidor de b-raf
AR077975A1 (es) * 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
CN102665720A (zh) * 2009-10-12 2012-09-12 葛兰素史密斯克莱有限责任公司 组合
US20120045433A1 (en) 2010-08-17 2012-02-23 Kapil Dhingra Combination therapy
MX360157B (es) * 2010-11-08 2018-10-24 Novartis Ag Uso de derivados de 2-carboxamida-cicloamino-urea en el tratamiento de enfermedades dependientes de egfr o de enfermedades que han adquirido resistencia a los agentes que tienen como objetivo los miembros de la familia egfr.
CA2855245A1 (en) 2011-11-10 2013-05-16 Memorial Sloan-Kettering Cancer Center Treatment of ovarian cancer with 2-amino-4h-naphtho[1,2-b]pyran-3-carbonitriles
AU2012335663B2 (en) * 2011-11-11 2015-12-24 Array Biopharma Inc. Method of treating a proliferative disease
EA028420B1 (ru) * 2012-08-07 2017-11-30 Новартис Аг Фармацевтические комбинации, содержащие ингибитор b-raf, ингибитор egfr и, необязательно, ингибитор pi3k-альфа

Also Published As

Publication number Publication date
DK2882440T3 (da) 2019-05-06
ECSP15008695A (es) 2019-03-29
SI2882440T1 (sl) 2019-05-31
AU2013299841A8 (en) 2017-01-05
CN104519887A (zh) 2015-04-15
WO2014025688A1 (en) 2014-02-13
HUE042877T2 (hu) 2019-07-29
GT201500025A (es) 2017-09-28
JP6595024B2 (ja) 2019-10-23
JP2018109022A (ja) 2018-07-12
BR112015002384A8 (pt) 2023-01-31
ES2717911T3 (es) 2019-06-26
HRP20190537T1 (hr) 2019-06-28
US20150265616A1 (en) 2015-09-24
BR112015002384A2 (pt) 2017-07-04
EP2882440A1 (en) 2015-06-17
PH12015500246B1 (en) 2015-03-30
HK1211831A1 (zh) 2016-06-03
EA201590332A1 (ru) 2015-06-30
CA2879548A1 (en) 2014-02-13
EP3574904A1 (en) 2019-12-04
EA028420B1 (ru) 2017-11-30
MX359403B (es) 2018-09-26
IN2015DN00450A (OSRAM) 2015-06-26
SG11201500321YA (en) 2015-04-29
MA37829A1 (fr) 2017-01-31
AU2013299841B8 (en) 2017-01-05
PL2882440T3 (pl) 2019-07-31
JP6342396B2 (ja) 2018-06-13
KR102112885B1 (ko) 2020-05-19
TN2015000027A1 (en) 2016-06-29
PE20150673A1 (es) 2015-05-20
CO7200273A2 (es) 2015-02-27
PE20191655A1 (es) 2019-11-07
IL236934B (en) 2018-11-29
TR201904980T4 (tr) 2019-05-21
TWI607754B (zh) 2017-12-11
CL2015000294A1 (es) 2015-05-08
CY1122143T1 (el) 2020-11-25
US9474754B2 (en) 2016-10-25
MX2015001732A (es) 2015-06-03
MY176031A (en) 2020-07-22
AU2013299841A1 (en) 2015-02-12
EP2882440B1 (en) 2019-02-27
PH12015500246A1 (en) 2015-03-30
PT2882440T (pt) 2019-04-23
CA2879548C (en) 2020-07-21
NZ703940A (en) 2018-04-27
AR092045A1 (es) 2015-03-18
JP6974669B2 (ja) 2021-12-01
JP2015524472A (ja) 2015-08-24
CN104519887B (zh) 2017-06-27
UA115786C2 (uk) 2017-12-26
JOP20130236B1 (ar) 2021-08-17
TW201410247A (zh) 2014-03-16
JP2020019780A (ja) 2020-02-06
RS58734B1 (sr) 2019-06-28
KR20150040905A (ko) 2015-04-15
AU2013299841B2 (en) 2016-11-24
HK1204976A1 (en) 2015-12-11

Similar Documents

Publication Publication Date Title
SG11201500321YA (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
GB201218801D0 (en) Device,method and software
IL235826A0 (en) Diazaspirocycloalkane and azaspirocycloalkane
IL234850A0 (en) Rapid aneuploidy detection
EP2821748A4 (en) DEVICE FOR FINDING A BEACH AND METHOD FOR FINDING A BEACH
EP2868008A4 (en) SIMULTANEOUS TRANSMISSION AND RECEPTION
HUE036907T2 (hu) Egyidejû adás és vétel
PL2831055T3 (pl) Zdolne do polimeryzacji alkilideno-1,3-dioksolan-2-ony i ich zastosowanie
GB201906245D0 (en) A method and device
EP2903772A4 (en) MATERIALS, METHODS AND DEVICES FOR CONNECTING LINES
IL237926A0 (en) Combinations and their uses
EP2806084A4 (en) SHAPING DEVICE AND CONSTRUCTION PROCESS WITH THE FORMING DEVICE
SG11201404617SA (en) Mixing device, discharge device provided therewith, and discharge method
ZA201206179B (en) Software fingerprinting
SG11201501033UA (en) A device and a method for anastomosis
EP2894608A4 (en) DISPLAY DEVICE, DISPLAY PROCEDURE AND PROGRAM
EP2806020A4 (en) PERSON SELECTION DEVICE AND PERSON SELECTION PROCEDURE
IL235919A0 (en) inhibitors of fbxo3
SG11201505068RA (en) Drawing device and drawing method
SG11201504482VA (en) Beta-hexosyl-transferases and uses thereof
EP2836857A4 (en) COUPLER, PROCESS AND APPLICATIONS
EP2850785A4 (en) METHODS AND DEVICES FOR INITIATING A COMPLEMENTARY APPLICATION
AU2013200291A1 (en) Methods and devices for context set selection
EP2858280A4 (en) METHOD OF ESTABLISHING ROADS AND DEVICE THEREOF
SG11201501838RA (en) Completion assembly and methods for use thereof